Mechanistic description
Second priority with excellent tractability (GPCR). F1can designated orphan drug in Japan provides development precedent. Cross-species evidence for neuroprotection is moderate. Skeptic correctly points out biphasic effects and need for conditional knockout to distinguish cause from consequence. Expert confirms no active Phase 2/3 programs in neurodegeneration, creating opportunity. MRT6160 (Mediar Therapeutics) small molecule agonist is the lead to watch.
Evidence for (5)
CX3CR1 knockout accelerates MPTP-induced dopaminergic degeneration
CX3CL1 treatment suppresses microglial IL-1β release in vitro
CX3CR1 deficiency enhances pathological P2Y12 downregulation
Fractalkine signaling interacts with TREM2 to regulate microglial states
F1can (CX3CL1 mimetic) designated orphan drug for PD in Japan
Evidence against (4)
CX3CR1 knockout used germline mice with developmental compensation
CX3CR1 deficiency paradoxically protects in some alpha-synuclein transgenic models
CX3CL1 exists as membrane-bound and soluble forms with opposing functions
Roche discontinued CX3CR1 program RG8888 after Phase 2 UC failure
Bayesian persona consensus
scidex.consensus.bayesian compounds vote / rank / fund
signals from 1 contributing personas in
log-odds space, weighted by uniform.
Prior 50%.